"In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile."@en . . . . . "# Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9605239"@en . . . . . . . . "* 2.66 mL/min/kg [Healthy Young Adult Patients] * 1.23 mL/min/kg [Kidney Transplant Patients] * 2.3 mL/min/kg [Liver Transplant Patients] * 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)] * 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]"@en . . . . "Doxacurium chloride"@en . . . . . "106819-53-8"@en . . . "Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia."@en . . . . "Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine."@en . . "Doxacurium"@en . . "* 0.11-0.43 L/kg [Healthy Young Adult Patients] * 0.17-0.55 L/kg [Kidney Transplant Patients] * 0.17-0.35 L/kg [Liver Transplant Patients]"@en . "Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration."@en . . "99 minutes in normal healthy adults."@en . . . . . . . "Humans and other mammals"@en . . . . . . . "approved"@en . . . "Approximately 30%."@en . . "Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation."@en . .